

19 October 2026

ASX Announcement

USAMRIID Marburg NHP study advances as 22 non-human primates successfully complete screening

- **Screening and preparation requirements completed for 22 non-human primates (NHP) for planned 20-animal Galidesivir dose optimisation study at USAMRIID**
- **All NHPs have passed rigorous health and suitability assessments under strict conditions**
- **All NHPs have also completed specialised training requirements, including acclimatisation to jackets and tethering systems required for the study**
- **Completion of animal screening and preparation represents an important operational milestone prior to dosing this quarter**
- **The study will evaluate Galidesivir against the Angola strain of Marburg virus, generating critical dose optimisation, pharmacokinetic and efficacy data**
- **Forms part of a coordinated development program alongside pending Texas Biomed study - designed to address complementary treatment settings**
- **Combined studies intended to progressively expand Galidesivir efficacy dataset and inform the design of pivotal study under the FDA Animal Rule pathway**
- **Study observations expected to conclude 30 days following commencement, with topline results to follow completion and analysis**
- **Program builds on over US\$70m of prior US Government investment in Galidesivir and an established body of efficacy and safety data**

MELBOURNE Australia, 19 October 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise that 22 non-human primates ("NHPs") have successfully completed screening and preparation requirements ahead of its planned 20-animal Galidesivir dose optimisation study at the United States Army Medical Research Institute of Infectious Diseases ("USAMRIID").

The successful completion of screening and preparation activities confirms that sufficient qualified animals are available for the planned study, with 20 NHPs required for participation and an additional two available as reserves. This represents an important operational milestone in the Company's Galidesivir development program, with dosing anticipated to commence during the current quarter (Q4 CY2026).

In preparation for the study, all 22 NHPs have undergone rigorous health and suitability assessments, together with a structured program of specialised training to prepare them for study procedures and pharmacokinetic ("PK") sampling.

This included progressive acclimatisation to specialised jackets and tethering equipment, which will be used during the administration of treatment and serial collection of blood samples. The training familiarises animals with the equipment and study environment ahead of dosing, supporting animal welfare and facilitating the reliable collection of PK and other study data.



The successful completion of these requirements represents a critical preparatory step ahead of Island's first Galidesivir study with USAMRIID, with the necessary animal screening, acclimatisation and training activities now completed.

The study is being undertaken as part of Island's Cooperative Research and Development Agreement ("CRADA") with USAMRIID and The Geneva Foundation and will be conducted within USAMRIID's specialised Biosafety Level 4 ("BSL-4") facilities.

The 20-NHP study will evaluate the efficacy of Galidesivir against the Angola strain of Marburg virus, with treatment initiated either 24- or 48-hours following exposure. Varying dose regimens will be administered intravenously over a 14-day treatment period, with the primary endpoint assessing survival at 28 days post-exposure, supported by assessments of viral load, clinical signs, pharmacokinetics and other disease-related parameters.

Study observations are expected to conclude ~30 days following commencement, with topline results anticipated following completion of the study and analysis of the resulting data.

The study forms a key component of Island's US Food and Drug Administration ("FDA") aligned development pathway for Galidesivir under the Animal Rule, which provides a potential regulatory approval pathway for treatments targeting diseases where human efficacy trials are not ethical or feasible.

Data generated from the USAMRIID study will support the optimisation of Galidesivir dosing and treatment parameters, informing dose selection and the design of the Company's planned pivotal confirmatory efficacy study.

Island is also progressing a 12-NHP study at Texas Biomedical Research Institute, which will evaluate Galidesivir treatment initiated following the onset of clinical disease. Together, the USAMRIID and Texas Biomed studies are designed to evaluate Galidesivir across complementary treatment settings, progressively expanding the available efficacy dataset and supporting the Company's planned pivotal development program under the FDA Animal Rule pathway.

The broader Galidesivir development program builds upon over US\$70m in prior US Government investment and an established body of preclinical and clinical safety and efficacy data. This includes previously generated NHP data demonstrating approximately 94% survival in Galidesivir-treated animals infected with the Marburg Musoke strain, compared with no survival in placebo-treated controls.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"The successful completion of screening and preparation activities for 22 animals is another important milestone for our Galidesivir program and reflects the considerable work being undertaken with our partners at USAMRIID ahead of study commencement."*

"These are highly specialised studies, requiring extensive preparation to ensure animals meet the necessary health, training and procedural requirements. Having successfully prepared 22 animals for our planned 20-animal study, including two reserves, is a pleasing outcome and provides a strong foundation as we progress towards dosing during the current quarter."



"Importantly, the USAMRIID study represents a critical component of our FDA-aligned development pathway for Galidesivir. Alongside our planned Texas Biomed study, the data generated will help establish optimal dosing parameters and treatment windows, informing the design of our pivotal efficacy study and advancing our objective of developing Galidesivir as a potential treatment for Marburg Virus Disease. We look forward to commencing dosing and providing further updates as the program progresses."

- Ends -

Approved for release to the ASX by:

The Board of Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.